Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Abeona Therapeutics

NASDAQ: ABEO ↗$2.42 USD~$145M MCAP

Commercial-stage cell and gene therapy company. Its ZEVASKYN (prademagene zamikeracel) autologous cell sheet was approved by the FDA in April 2025 for recessive dystrophic epidermolysis bullosa, and FAYUVI (ABO-102) became the company's second approved gene therapy in 2026 for mucopolysaccharidosis type IIIA. Abeona added APT-1011 (ABO-801), a Phase 3-ready orally disintegrating fluticasone formulation for eosinophilic esophagitis, in November 2026 and is advancing its SIR-T synthetic immune receptor platform, led by PSMA-targeted ABO-701 for advanced prostate cancer.

Company Info

Sector:Cell & Gene Therapy
Headquarters:Cleveland, OH, USA
Founded:2015

Clinical Development Pipeline

ZEVASKYN (prademagene zamikeracel)

Target: COL7A1 gene-corrected autologous cell sheet
Recessive dystrophic epidermolysis bullosa
Preclinical
Phase 1
Phase 2
Phase 3
Approved

FAYUVI (ABO-102)

Target: AAV9-mediated SGSH gene therapy
Mucopolysaccharidosis type IIIA
Preclinical
Phase 1
Phase 2
Phase 3
Approved

APT-1011 (ABO-801)

Target: Fluticasone propionate orally disintegrating tablet
Eosinophilic esophagitis
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

No recent news updates available for this company.

Leadership Team

Vishwas Seshadri

President & Chief Executive Officer

Joseph Vazzano

Chief Financial Officer

Careers & Job Openings

See all open roles

Multiple Departments
Cleveland, OH
Apply Now →